The DOI matches its Crossref record.
Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes.
Abstract
Investigation of the naturally occurring, nicotinic agonist anabaseine and novel derivatives has shown that these compounds have cytoprotective and memory-enhancing effects. The hypothesis that these arise at least in part through actions on brain nicotinic receptors was evaluated by examining the ability of these compounds to displace the binding of nicotinic ligands and to affect the function of the alpha 4 beta 2 and alpha 7 receptor subtypes expressed in Xenopus oocytes. The derivative 3-(4)-dimethylaminocinnamylidine anabaseine (DMAC) was found to be a selective alpha 7 receptor agonist; it was more potent than nicotine, acetylcholine, anabaseine, and other derivatives at activating the alpha 7 receptor subtype, while displaying little agonist activity at alpha 4 beta 2 and other receptor subtypes. Compared with anabaseine and the other derivatives, DMAC was the most potent at displacing 125I-alpha-bungarotoxin binding (putative alpha 7) and the least potent at displacing [3H]cytisine binding (putative alpha 4 beta 2) to brain membranes. Independently of agonist activities, all of the novel compounds displayed secondary inhibitory activity at both receptor subtypes. At the alpha 4 beta 2 receptor subtype, inhibition by the 3-(2,4)-dimethoxybenzylidene derivative was enhanced by coapplication of acetylcholine, suggesting a noncompetitive form of inhibition. Anabaseine and nicotine prolonged the time course of activation of alpha 4 beta 2 receptors, compared with acetylcholine, suggesting sequential channel-blocking activity. As selective agonists, anabaseine derivatives such as DMAC may be useful for elucidating the function of alpha 7 nicotinic receptors, including their potential role(s) in the cytoprotective and memory-enhancing effects of nicotinic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia
Olincy, A., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G. O., Leonard, S., Stevens, K. E., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.630 · Cited by 527
Self-citationHuman neuronal nicotinic receptors
Gotti, C., Fornasari, D., & Clementi, F. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00034-8 · Cited by 416
Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia
Martin, L., Kem, W., & Freedman, R. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1750-1 · Cited by 342
Self-citationEffects of Ethanol on Ion Channels
Crews, F. T., Morrow, A. L., Criswell, H., & Breese, G. (1996) · International Review of Neurobiology · doi:10.1016/s0074-7742(08)60670-4 · Cited by 299
Papke, R. L., Bencherif, M., & Lippiello, P. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12889-5 · Cited by 275
Self-citation
Metadata
- Authors
- de Fiebre, C. M., Meyer, E. M., Henry, J. C., Muraskin, S. I., Kem, W. R., & Papke, R. L.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 1995-01
- Volume
- 47
- Issue
- 1
- Pages
- 164-171
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W2338521704
- Cited by
- 197
- References
- 0
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes. https://app.cochat.ai/papers/10.1016/s0026-895x(25)08515-3
- The paper
- de Fiebre, C. M., Meyer, E. M., Henry, J. C., Muraskin, S. I., Kem, W. R., & Papke, R. L. (1995). Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes. Molecular Pharmacology. https://doi.org/10.1016/s0026-895x(25)08515-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.